J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group
Judith G. Villablanca,Wendy B. London,Wendy B. London,Arlene Naranjo,Arlene Naranjo,Patrick McGrady,Patrick McGrady,Matthew M. Ames,Joel M. Reid,Renee M. McGovern,Sarah A. Buhrow,Hollie A. Jackson,Enno Stranzinger,Brenda J. Kitchen,Paul M. Sondel,Marguerite T. Parisi,Barry L. Shulkin,Gregory A. Yanik,Susan L. Cohn,C. Patrick Reynolds +19 more
TL;DR: Although neither stratum met protocol criteria for efficacy, 1 PR + 13 prolonged SD occurred in 14/59 (24%) of evaluable patients, suggesting low bioavailability may have limited fenretinide activity.
Journal ArticleDOI
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Lars M. Wagner,John P. Perentesis,Joel M. Reid,Matthew M. Ames,Stephanie L. Safgren,Marvin D. Nelson,Ashish M. Ingle,Susan M. Blaney,Peter C. Adamson +8 more
TL;DR: This work examined this three‐drug combination in children with relapsed solid tumors, using cefixime to reduce irinotecan‐associated diarrhea.
Journal ArticleDOI
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
Jodi A. Muscal,Patrick A. Thompson,Terzah M. Horton,Ashish M. Ingle,Charlotte H. Ahern,Renee M. McGovern,Joel M. Reid,Matthew M. Ames,Igor Espinoza-Delgado,Brenda J. Weigel,Susan M. Blaney +10 more
TL;DR: A pediatric Phase I trial was performed to determine the maximum‐tolerated dose, dose‐limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors.
Journal ArticleDOI
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide
Cheri E. Klein,Cheri E. Klein,Elora Gupta,Elora Gupta,Joel M. Reid,Joel M. Reid,Pamela J. Atherton,Pamela J. Atherton,Jeff A. Sloan,Jeff A. Sloan,Henry C. Pitot,Henry C. Pitot,Mark J. Ratain,Mark J. Ratain,Helen Kastrissios,Helen Kastrissios +15 more
TL;DR: The objective of the study was to develop and validate a population pharmacokinetic model for irinotecan and 2 of its metabolites, SN‐38 and SN‐ 38 glucuronide (SN‐38G).
Journal ArticleDOI
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Brenda J. Weigel,Susan M. Blaney,Joel M. Reid,Stephanie L. Safgren,Rochelle Bagatell,John H. Kersey,Joseph P. Neglia,S. Percy Ivy,Ashish M. Ingle,Luke Whitesell,Richard J. Gilbertson,Mark Krailo,Matthew M. Ames,Peter C. Adamson +13 more
TL;DR: Drug exposures consistent with those required for anticancer activity in preclinical models were achieved without DLT and non-DMSO–containing formulations may improve acceptance of this drug by children and their families.